Danaher (NYSE:DHR) PT Raised to $250.00

Danaher (NYSE:DHR) had its target price boosted by research analysts at The Goldman Sachs Group from $225.00 to $250.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the conglomerate’s stock. The Goldman Sachs Group’s target price indicates a potential downside of 7.44% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and upped their price target for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Barclays lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. TD Cowen upped their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Robert W. Baird lifted their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $276.88.

Danaher Trading Up 1.6 %

NYSE DHR opened at $270.09 on Wednesday. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $200.05 billion, a P/E ratio of 45.78, a P/E/G ratio of 4.11 and a beta of 0.83. Danaher has a 52-week low of $182.09 and a 52-week high of $276.31. The firm has a 50-day moving average price of $254.99 and a 200 day moving average price of $248.82.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 10.90% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $2.05 EPS. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. Equities research analysts expect that Danaher will post 7.62 EPS for the current year.

Insider Transactions at Danaher

In related news, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold 75,175 shares of company stock worth $19,161,154 over the last quarter. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Patrick M Sweeney & Associates Inc. increased its position in Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares in the last quarter. Trust Co of Kansas grew its stake in Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after buying an additional 40 shares during the period. ST Germain D J Co. Inc. increased its position in shares of Danaher by 1.4% in the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after acquiring an additional 41 shares in the last quarter. Godsey & Gibb Inc. raised its stake in shares of Danaher by 3.0% in the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after acquiring an additional 42 shares during the period. Finally, Premier Path Wealth Partners LLC lifted its holdings in shares of Danaher by 1.8% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock valued at $586,000 after acquiring an additional 42 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.